The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK agrees deals for 114 million more Moderna and Pfizer COVID-19 doses

Wed, 01st Dec 2021 22:30

By Michael Holden

LONDON, Dec 1 (Reuters) - Britain said on Wednesday it had
agreed deals to buy 114 million more Pfizer/BioNTech and Moderna
COVID-19 vaccine shots, saying it had sped up signing the new
contracts in light of the emergence of the new Omicron variant.

The deal involves an additional 60 million Moderna
shots and 54 million Pfizer doses for next year and
2023, and will also include access to any modified vaccinations
if they are needed to combat the Omicron strain or any other
variant, the British health ministry said.

"These new deals will future proof the Great British
vaccination effort – which has so far delivered more than 115
million first, second and booster jabs across the UK – and will
ensure we can protect even more people in the years ahead,"
health minister Sajid Javid said.

So far, nearly 51 million people in Britain have received
their first COVID vaccine - almost 89% of the population aged
over 12, more than 46 million have had two doses, and some 18.6
million have received a booster shot.

On Tuesday Prime Minister Boris Johnson announced a new
target this week to offer all adults a vaccine booster by the
end of January, which means speeding up the rollout by an extra
million doses a week.

So far 32 cases of the heavily mutated Omicron variant,
which it is feared could be more transmissible, have been
identified in Britain which has sparked the government into
ramping out the vaccine programme.

Britain has made it mandatory to wear masks on public
transport and shops, but Johnson and his ministers hope the
booster programme will mean there will be no need for further
restrictions or measures to curb social gatherings.

The contracts for the additional vaccines come on top of an
order for 35 million Pfizer shots made in August for the second
half of next year, and for 60 million Novavax and 7.5 million
GlaxoSmithKline (GSK)/Sanofi doses which are due in 2022 but are
yet to be approved by the British regulator.

Wealthy countries have been accused of not doing enough to
distribute stockpiles of vaccines to poorer nations, and the
British government said it remained committed to donating 100
million doses by the middle of 2022, saying 30 million would be
donated by the end of this year.

Johnson will also on Thursday host a roundtable of leaders
from major pharmaceutical firms including AstraZeneca, GSK and
Pfizer to discuss preparations to deal with any future
pandemics.
(Reporting by Michael Holden; editing by David Evans)

More News
11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

*

Read more
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.